Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Surgiflo
- Development stage
- Phase 1
- Lead developer
- Ethicon
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Surgiflo is a flowable hemostatic matrix composed of porcine-derived gelatin and human-derived thrombin. It is designed to provide a physical scaffold for clot formation while actively promoting the coagulation cascade through the enzymatic action of thrombin, which converts fibrinogen into fibrin. Developed and manufactured by Ethicon (a Johnson & Johnson company), Surgiflo is primarily used in surgical settings to control bleeding (hemostasis) when conventional techniques like ligation or cautery are ineffective or impractical. It is frequently utilized in orthopedic, vascular, and general surgery to reduce perioperative and postoperative blood loss.
- Brand names
- Surgiflo
- Other names
- Surgiflo Hemostatic Matrix
Beyond the preview
Go deeper on Surgiflo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Surgiflo.